Mirabegron
- Generic Name
- Mirabegron
- Brand Names
- Myrbetriq, Betmiga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24N4O2S
- CAS Number
- 223673-61-8
- Unique Ingredient Identifier
- MVR3JL3B2V
- Background
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is respons...
- Indication
Mirabegron is indicated for the treatment of overactive bladder (OAB) - with symptoms of urge urinary incontinence, urgency, and urinary frequency - either alone or in combination with solifenacin. It is also indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35kg or more.
- Associated Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 20
- Registration Number
- NCT02169713
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 376
- Registration Number
- NCT02138747
- Locations
- 🇺🇸
Site US10010 Skyline Urology, Sherman Oaks, California, United States
🇨🇦Site CA15003 The Male/Female Health & Research Centre, Barrie, Ontario, Canada
🇺🇸Site US10035 Millennium Clinical Research Center, Arlington, Virginia, United States
Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 26
- Registration Number
- NCT02127034
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
Ureteral Stent-related Pain and Mirabegron (SPAM) Trial
- Conditions
- Interventions
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Nova Scotia Health Authority
- Target Recruit Count
- 22
- Registration Number
- NCT02095665
- Locations
- 🇨🇦
Nova Scotia Health Authority, Central, Halifax, Nova Scotia, Canada
A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Daniel Burdick, MD
- Target Recruit Count
- 30
- Registration Number
- NCT02092181
- Locations
- 🇺🇸
Evergreenhealth Booth Gardner Parkinsons Care Center, Kirkland, Washington, United States
Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis
- First Posted Date
- 2014-03-13
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Theodore R. Brown, MD MPH
- Target Recruit Count
- 28
- Registration Number
- NCT02086188
- Locations
- 🇺🇸
EvergreenHealth MS Center, Kirkland, Washington, United States
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 1829
- Registration Number
- NCT02045862
- Locations
- 🇺🇸
Site US10133, Los Angeles, California, United States
🇺🇸Site US10553, Lincoln, Nebraska, United States
🇺🇸Site US10148, Hialeah, Florida, United States
Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 32
- Registration Number
- NCT02044510
- Locations
- 🇨🇦
Rehabiliation Center, Health Sciences Center, Winnipeg, Manitoba, Canada
🇨🇦Toronto Western Hospital, Toronto, Ontario, Canada
🇨🇦Kingston General Hospital and Hotel Dieu Hospital (Queens University), Kingston, Ontario, Canada
A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels
- Conditions
- Interventions
- First Posted Date
- 2013-12-13
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 72
- Registration Number
- NCT02010944
- Locations
- 🇩🇪
Parexel, Berlin, Germany
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 3527
- Registration Number
- NCT01972841
- Locations
- 🇩🇪
Site DE49034 LMU Muenchen, Munich, Germany
🇩🇪Site DE49001 Private Practice, Neustadt I. Sachsen, Germany
🇺🇸Site US10064 The Group for Women, Virginia Beach, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.